Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results
Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study. Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel…